Silence Therapeutics Plc ADR (SLN)

$6.17 +0.01 (0.16%)
Market Cap 184.37M
Revenue (ttm) 43.26M
Net Income (ttm) -45.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -104.74%
Debt to Equity Ratio 0.00
Volume 62,200
Avg Vol 107,260
Day's Range N/A - N/A
Shares Out 29.93M
Stochastic %K 56%
Beta 1.39
Analysts Strong Sell
Price Target $32.17

Company Profile

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3457 6900
Address:
72 Hammersmith Road, London, United Kingdom
ngs1135
ngs1135 Jul. 25 at 4:40 PM
$SLN added more
0 · Reply
LIGator
LIGator Jul. 23 at 6:37 PM
$SLN so much Tomfuckery going on. Someone is selling well below the VWAP trying to spoof a panic. Griffith just announced he bought 25,000 shares at an average price of $6.05 in the past 2 days.
1 · Reply
inquisitive1
inquisitive1 Jul. 17 at 4:50 PM
$SLN LIGator, hope your conviction pans out.
1 · Reply
LIGator
LIGator Jul. 17 at 2:31 PM
$SLN Griffiths bought more last week at an average price of $6.41. He has 11.7 million shares and he is still adding in the $6’s. I will add as well.
0 · Reply
inquisitive1
inquisitive1 Jul. 16 at 7:47 PM
$SLN Hi, wanted to let people know I sold my position earlier today, at a miniscule gain. I only held the stock for 1 week, but I'm concerned it may trade back below $6. The proceeds from the sale were used to purchase Lattice (LSCC).
0 · Reply
inquisitive1
inquisitive1 Jul. 15 at 8:06 PM
$SLN Volume picking up some today, with an impressive close.
0 · Reply
inquisitive1
inquisitive1 Jul. 14 at 3:37 PM
$SLN So, without a partner to bring a drug to market, is this stock doomed?
2 · Reply
TopAlrt
TopAlrt Jul. 11 at 2:28 PM
$SLN +24.4% since first alert 🔥 $SLNH at 1.33 Float: 1.2M | Short: 11.4 % Rel. Vol.: 435.6x | Vol.: 53.6K $ USA | Information Technology Services SSR: OFFH
0 · Reply
inquisitive1
inquisitive1 Jul. 11 at 1:29 AM
$SLN My error on my previous post from today. I purchased shares of SLN yesterday at $6.40, not $8.40.
0 · Reply
JoeMoney3
JoeMoney3 Jul. 11 at 12:30 AM
$SLN
0 · Reply
Latest News on SLN
Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

Jun 12, 2025, 4:01 PM EDT - 7 weeks ago

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 3 months ago

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025, 7:45 AM EDT - 3 months ago

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Mar 5, 2025, 8:00 AM EST - 5 months ago

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 11:59 AM EST - 5 months ago

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:30 AM EST - 5 months ago

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Feb 13, 2025, 8:00 AM EST - 6 months ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Top 3 Health Care Stocks That May Explode In Q4

Dec 18, 2024, 7:46 AM EST - 8 months ago

Top 3 Health Care Stocks That May Explode In Q4

MODV OLMA

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Dec 9, 2024, 7:30 AM EST - 8 months ago

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 8:00 AM EST - 8 months ago

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Nov 19, 2024, 3:34 PM EST - 9 months ago

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Top 3 Health Care Stocks You'll Regret Missing In Q4

Nov 19, 2024, 7:52 AM EST - 9 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

AMRN TERN

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Nov 18, 2024, 2:30 PM EST - 9 months ago

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 9 months ago

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 9 months ago

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'

Sep 8, 2024, 9:13 AM EDT - 11 months ago

Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'

Silence: Additional siRNA Drug Data Leads To Next Stages Of Development

Sep 5, 2024, 2:18 PM EDT - 11 months ago

Silence: Additional siRNA Drug Data Leads To Next Stages Of Development

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 15, 2024, 7:30 AM EDT - 1 year ago

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Jun 27, 2024, 7:30 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results

Jun 21, 2024, 2:31 PM EDT - 1 year ago

Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Jun 20, 2024, 7:30 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

May 30, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

May 16, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Apr 29, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Apr 8, 2024, 11:48 AM EDT - 1 year ago

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 10:01 AM EDT - 1 year ago

Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 13, 2024, 7:05 AM EDT - 1 year ago

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Feb 28, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

Feb 24, 2024, 8:53 PM EST - 1 year ago

Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Feb 23, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Feb 5, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 7:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Dec 1, 2023, 7:00 AM EST - 1 year ago

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Nov 14, 2023, 7:00 AM EST - 1 year ago

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 1 year ago

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Silence Therapeutics to Participate in September Investor Conferences

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics to Participate in September Investor Conferences

Silence Therapeutics Reports Second Quarter 2023 Results

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Reports Second Quarter 2023 Results

Silence Therapeutics: No Reason For It To Fall So Much

Jul 14, 2023, 7:15 PM EDT - 2 years ago

Silence Therapeutics: No Reason For It To Fall So Much

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

Jul 11, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration

Silence Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics to Present at the Jefferies Healthcare Conference

Silence Therapeutics Reports First Quarter 2023 Results

May 16, 2023, 4:00 PM EDT - 2 years ago

Silence Therapeutics Reports First Quarter 2023 Results

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

May 4, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

May 1, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

Apr 25, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference

ngs1135
ngs1135 Jul. 25 at 4:40 PM
$SLN added more
0 · Reply
LIGator
LIGator Jul. 23 at 6:37 PM
$SLN so much Tomfuckery going on. Someone is selling well below the VWAP trying to spoof a panic. Griffith just announced he bought 25,000 shares at an average price of $6.05 in the past 2 days.
1 · Reply
inquisitive1
inquisitive1 Jul. 17 at 4:50 PM
$SLN LIGator, hope your conviction pans out.
1 · Reply
LIGator
LIGator Jul. 17 at 2:31 PM
$SLN Griffiths bought more last week at an average price of $6.41. He has 11.7 million shares and he is still adding in the $6’s. I will add as well.
0 · Reply
inquisitive1
inquisitive1 Jul. 16 at 7:47 PM
$SLN Hi, wanted to let people know I sold my position earlier today, at a miniscule gain. I only held the stock for 1 week, but I'm concerned it may trade back below $6. The proceeds from the sale were used to purchase Lattice (LSCC).
0 · Reply
inquisitive1
inquisitive1 Jul. 15 at 8:06 PM
$SLN Volume picking up some today, with an impressive close.
0 · Reply
inquisitive1
inquisitive1 Jul. 14 at 3:37 PM
$SLN So, without a partner to bring a drug to market, is this stock doomed?
2 · Reply
TopAlrt
TopAlrt Jul. 11 at 2:28 PM
$SLN +24.4% since first alert 🔥 $SLNH at 1.33 Float: 1.2M | Short: 11.4 % Rel. Vol.: 435.6x | Vol.: 53.6K $ USA | Information Technology Services SSR: OFFH
0 · Reply
inquisitive1
inquisitive1 Jul. 11 at 1:29 AM
$SLN My error on my previous post from today. I purchased shares of SLN yesterday at $6.40, not $8.40.
0 · Reply
JoeMoney3
JoeMoney3 Jul. 11 at 12:30 AM
$SLN
0 · Reply
inquisitive1
inquisitive1 Jul. 10 at 8:53 PM
$SLN Prior to yesterday, I have been in and out of SLN twice from last December to this February: one successful trade and one unsuccesful trade. Yesterday afternoon, near closing of the markets, I purchased shares at $8.40, with proceeds from a massive gain in JOBY in a one-week period (JOBY is up strongly today as well). Two questions: Why does SLN have such low average volume? And do you expect the volume to increase?
1 · Reply
AMWG42isback
AMWG42isback Jul. 10 at 3:17 PM
$SLN hold guys
0 · Reply
AMWG42isback
AMWG42isback Jul. 9 at 8:11 PM
$SLN WOOF what a day yall. Let’s finish the week strong. No walls till 7.00 let’s gooooooo
0 · Reply
AMWG42isback
AMWG42isback Jul. 9 at 4:48 PM
$SLN FAKE wall at 6.25
0 · Reply
AMWG42isback
AMWG42isback Jul. 8 at 2:20 PM
$SLN 6.14 every FUCKING time.
1 · Reply
LIGator
LIGator Jul. 8 at 1:49 PM
$SLN six is good. Sixteen would be great.
0 · Reply
AMWG42isback
AMWG42isback Jul. 2 at 2:41 PM
$SLN I am once again reminding everyone there are no walls till 7.00
0 · Reply
Quantumup
Quantumup Jul. 1 at 1:08 PM
Barclays⬆️ $IONS to Overweight-$57 from Equalweight-$51. $ARWR $AMGN $LLY $SLN NVS Barclays said in its $IONS Upgrade and PT Increase: "Ahead of Tryngolza Ph3 CORE/CORE2 data (3Q25, likely Sept) in severe hypertriglyceridemia (sHTG), we spoke with three #KOLs and did a deep dive on historical clinical trials, natural history data, and statistical analysis. We see a high prob (>90%) it will hit the primary endpoint of triglyceride (TG) % change from baseline. We also see a high prob (>90%) it will hit all key 2nd biomarker endpoints prior to acute pancreatitis (AP) analysis per stats hierarchy. For key 2nd endpoint of AP, we see a ~50-55% probability it will hit stat sig. Based on our #KOL feedback, we would view a stat sig AP benefit as unprecedented and consider a trend of AP benefit to be clinically meaningful. Upgrade to OW and raise our PT to $57."
0 · Reply
AMWG42isback
AMWG42isback Jun. 27 at 3:09 PM
$SLN no walls till 7.00. This has to test 6.14 again, then 6.30, and needs to find support around 6.00 to leg up anymore.
0 · Reply
AMWG42isback
AMWG42isback Jun. 26 at 1:33 PM
$SLN wow
0 · Reply
AMWG42isback
AMWG42isback Jun. 25 at 1:41 PM
$SLN and just like that, all those gains are gone with 1 fuckin trade
0 · Reply
LIGator
LIGator Jun. 24 at 7:31 PM
$SLN has not closed above $6 since February. Today could be the day. The VWAP Is $6.12 so that would be a great close. Next goal is the 200 average above $8. The January 2026 $5 calls are waking up.
0 · Reply